Stepping in for Patients with Inflammatory Bowel DiseasePremiere Date: Friday, May 20, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, May 20, 2017
Note: Credit Is No Longer Available
|Miguel Regueiro, MD, AGAF, FACG, FACP
Professor and Chair
Department of Gastroenterology, Hepatology & Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
|Lawrence R. Kosinski, MD, MBA, AGAF, FACG
Managing Partner, Illinois Gastroenterology Group
Communicty Private Practice Councillor, AGA Governing Board
President, SonarMD, LLC
|Eva M. Szigethy, MD, PhD, FACG
Professor of Psychiatry, Medicine & Pediatrics
Director, Behavioral Health within the Chief Medical and Scientific Office
Director, IBD Total Care Medical Home
University of Pittsburgh Medical Center
|Erin M. Lopata, PharmD
Manager, Clinical Pharmacy
University of Pittsburgh Medical Center (UPMC) Health Plan
Inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD are evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention. Education for clinicians who manage patients with moderate-to-severe IBD about the latest available options to individualize IBD treatment can reduce the use of corticosteroids and need for hospitalizations or surgery, resulting in decreased healthcare utilization and improved quality of life for these patients.
Expert faculty in this CME Outfitters enduring archive will provide needed education about the evolving science of IBD to inform and guide treatment selection, manage side effects, and personalize the clinical approach to care.
At the end of this CE activity, participants should be able to:
- Integrate the complexities of disease progression to facilitate decision making for patients with inflammatory bowel disease.
- Utilize a proactive, personalized approach weighing risk/benefit and cost when making decisions for patients with inflammatory bowel disease.
- Differentiate between mechanisms of action of therapies and how those differences translate to clinical decision-making in patients with inflammatory bowel disease.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, physician assistants, nurse practitioners, nurses, and pharmacists, managed care medical directors, managed care pharmacists, and other managed care professionals making decisions for patients with IBD.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hour
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hour of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-16-012-H01-P (recorded programs)
Activity Type: knowledge-based
Successful completion of this CE activity includes participating in the live activity, reviewing the course materials, within 30 days of completion of the activity, and completing your activity evaluation and post-test online (75% pass rate required). You may print your certificate or statement of credit immediately. Please visit www.CMEOutfitters.com/20071(requires free account activation).
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reguerio has disclosed that he serves as a consultant to AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Kosinski has disclosed that he serves as a consultant to Takeda Pharmaceuticals U.S.A., Inc.
Dr. Lopata has no disclosures to report.
Dr. Szigethy has disclosed that she has received research/grant support from the Crohn's & Colitis Foundation of America (CCFA). She is on the speakers bureau of AbbVie Inc. and Imedex (Honorarium for educational talk). She serves as a consultant to iHope Networks and AbbVie, Inc. She receives royalties from APPI (book editor).
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals U.S.A., Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).